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Abstract: (1) Background: Renal cancer is one of the most frequent malignancies in Western countries,
with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of
reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the
renin–angiotensin system (RAS) that has been associated with the development and progression
of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this
study, we analysed the immunohistochemical expression of PRR at the centre and border in a series
of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell
carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results: PRR is expressed in
all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression
of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated
with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA
integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated
with the development and progression of renal tumours. Its potential as a novel biomarker for RCC
diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future.
Keywords: renal cell carcinoma; (Pro)renin receptor; renin–angiotensin system; prognosis
1. Introduction
Renal cell carcinoma (RCC) is one of the most common malignancies in Western Coun-
tries [1–3]. Nearly half of all cases of RCC are diagnosed in people more than 65 years old [2,4].
The incidence of RCC has been steadily increasing in recent decades, and it is expected that
this trend will continue in the future due to the aging population of developed countries [4].
Clear-cell renal cell carcinoma (CCRCC) is by far the most frequent histological sub-
type of RCCs, accounting for approximately 75–80% of cases, followed by papillary renal
cell carcinoma (PRCC) (10–15%) and chromophobe renal cell carcinoma (ChRCC) (5%) [5].
The most commonly accepted origin of CCRCC and PRCC is the proximal convoluted
tubule of the nephron. ChRCC shares a common lineage with benign tumor renal on-
cocytoma (RO) (5%) and both seem to originate from the intercalated cells of the distal
Diagnostics 2021, 11, 272. https://doi.org/10.3390/diagnostics11020272 https://www.mdpi.com/journal/diagnostics
Diagnostics 2021, 11, 272 2 of 13
nephron [6]. CCRCC is the most aggressive of the RCCs; 30% of patients are metastatic
at diagnosis and another 30% of patients with localized disease eventually progress to
metastatic disease [5]. A close correlation between some specific genomic signatures and
clinical aggressiveness has been detected in recent studies [7], but an easier identification of
changes linked to tumour behaviour and clinical outcome is necessary to reach an efficient
improvement in the management of CCRCC patients [8]. With this regard, in recent years,
novel prognostic biomarkers and therapeutic approaches have been explored. Thus, study
of the components of the renin–angiotensin system (RAS) in the context of renal neoplasms
and the potential usefulness of drugs that target this peptidergic system has become a
promising research field for RCC [9].
The RAS has been traditionally described as a circulating hormone system that reg-
ulates cardiovascular and renal function [10]. However, RAS is also locally expressed in
several organs and tissues and its paracrine, autocrine, and intracrine signals can regulate
long-term biologic processes such as cell growth [9,11]. Thus, the discovery of intrarenal
RAS has been crucial to understanding its involvement in non-neoplastic chronic kidney
disease [9,12]. For years, angiotensin-converting enzyme (ACE) and angiotensin-II recep-
tor (AT1R) inhibitors (ACEis and ARBs) have been widely used in the management of
this pathology. The mechanism of action of these drugs is based on the inhibition of the
ACE/Ang-II/AT1R axis, which induce cell proliferation, fibrosis and inflammation [9,12].
These phenomena are also part of neoplastic processes and, therefore, the study of
RAS and the potential of RAS-targeting therapies has received considerable attention in
research into renal cancer [9,11]. Thus, imbalances in components of the intrarenal RAS,
such as the up-regulation of AT1Rs in RCC cells and ACE in tumour vessels, have been
associated with renal cancer development and progression [13–15]. Besides, the use of
the abovementioned RAS inhibitors (RASis) has been associated with better response to
current treatments and better outcomes of patients with metastatic RCC [16–18].
The (pro)renin receptor (PRR) is a novel component of the RAS that was first described
in the past decade [19] and that is expressed in several organs and tissues, including the
kidney [12]. The most well-known function of this protein is the activation of RAS. PRR
binds renin enzyme and its inactive precursor prorenin, which enhances their activity and
the production of angiotensin I, which is converted by ACE in angiotensin II, leading to
AT1R-mediated signals. PRR is also activated after the binding of (pro)renin, which leads
to PI3/AKT/mTOR and MAPK/ERK signalling [12,20,21]. Besides this, PRR is considered
to function as a hinge molecule between the Wnt receptor and the V-ATPase that mediates
Wnt receptor internalization and the subsequent Wnt/β–catenin signaling [12,21].
These RAS-dependent and -independent signalling pathways contribute to cancer initi-
ation, so it was expected that PRR expression could be altered in tumour tissues [21]. Thus,
increases in this protein have been described in pancreatic ductal adenocarcinoma [22,23],
glioma [24,25], colorectal [26,27], breast [28] and endometrial cancer [29]. Taking into ac-
count that PRR exerts important functions in kidney physiology and that it takes part in
inflammatory and fibrotic processes of this organ [12], changes in this protein can also be
expected in kidney neoplasms. The Cancer Genome Atlas (TCGA) described high mRNA
levels of PRR in RCCs when compared with the uninvolved part of the kidney [21]. The
Human Protein Atlas (https://www.proteinatlas.org (accessed on 5 February 2021)) de-
scribed PRR staining in RCCs; however, the analyses were limited to only 11 cases, which
was insufficient to understand the association between this protein and tumour progression.
In this study, we analysed PRR immunohistochemical expression in a series of 120 kid-
ney tumours. The series included three subtypes of RCC (CCRCC, PRCC and ChRCC) and
the benign tumour RO. Both the centre of the tumour and the infiltration front was analysed
to test the possible heterogeneity of PRR expression in these tumours. Since CCRCC is the
most frequent RCC [5], we analysed the association between PRR and tumour progression
and its impact on the prognosis of CCRCC patients.
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2. Materials and Methods
The present study, including all its experiments, comply with current Spanish and
European Union legal regulations. The Basque Biobank for Research (OEHUN) (www.
biobancovasco.org (accessed on 5 February 2021)) was the source of samples, and the data
from employed patients could possibly be used for research purposes. Each patient signed
a specific document which was approved by the Ethical and Scientific Committees of the
Basque Country Public Health System (Osakidetza) (PI + CES-BIOEF 2018-04).
2.1. Patients
A total of 120 renal tumours, surgically removed at Basurto University Hospital
between 2012 and 2016, were collected for the study: 83 CCRCCs (mean age: 61.9 years,
58 males and 25 females), 19 PRCCs (mean age: 53.5 years, 15 males and 4 females),
7 ChRCCs (63.9 years, 6 males and 1 female) and 11 ROs (mean age: 63.4 years, 4 males
and 7 females). Samples from the tumour centre and the infiltrating front were included in
tissue microarrays (TMAs) for further immunohistochemical analyses. One sample of the
uninvolved kidney was also included in each TMA.
Table 1 summarizes the pathological and clinical characteristics of patients with
CCRCC. American Joint Committee on Cancer (AJCC) [30] and WHO/ISUP [31] methods
were applied to assign tumour, node and metastasis (TNM) Stage and Grade, respectively.
Table 1. Pathological and clinical characteristics of clear cell renal cell (CCRCC) cancer patients.
WHO/ISUP: World Health Organization / International Society of Urologic Pathologists. TNM:
Tumour (T), Node (N), Metastasis (M). SSIGN: Stage, Size, Grade, and Necrosis. UISS: UCLA
Integrated Staging System.
Variables CCRCC Patients (n = 83)
Diameter
≤4 cm 26







Not confined pT3-pT4 18


















Variables CCRCC Patients (n = 83)
Patients’ Survival
Alive 62
Dead of disease 15
Dead by other causes 6
2.2. Immunohistochemistry
Rabbit polyclonal antibody specific for PRR [ref. HPA003156; Sigma-Aldrich
(Saint Louis, MO, USA) at 1/50 dilution] was used for the immunostaining of formalin-fixed
and paraffin-embedded tumour tissues. The antibody’s specificity was tested previously [27]
and the immunostaining process was performed following routine methods in an automatic
immunostainer (Dako Autostainer Plus, Dako-Agilent, Santa Clara, CA, USA). Briefly, anti-
gen retrieval was carried out in a low-pH buffer (K8005, Dako, Santa Clara, CA, USA) for
20 min at 95 ◦C. The samples were incubated with the primary antibody for 50 min at room
temperature. Then, the primary antibody was washed and samples were incubated for
20 min with secondary anti-rabbit antibody (K8021, Dako). EnVision-Flex detection system
together with an HRP-enzyme-labelled polymer (SM802, Dako) was employed. A positive
reaction was visualized with diaminobenzydine (DAB) solution (DM827, Dako), followed by
counterstaining with haematoxylin (K8008, Dako).
Slides were reviewed under light microscopy for staining evaluation. Two observers
independently evaluated the slides and, in the event of discrepancies, samples were re-
evaluated to arrive at a final conclusion. As previously reported [27], staining patterns
were scored as negative, weak and intense cytoplasmic and membranous staining.
2.3. Statistical Analysis
The statistical analysis was performed with SPSS® 24.0.
We applied a Kolmogorov–Smirnov test to assess if data obtained from tumour tissues
followed a normal distribution. Based on this information, data were further analysed
using parametric or non-parametric tests.
The correlation between PRR expression in tumour centre and front and patient age
and gender was evaluated using Spearman Rho tests. Associations between categorical
PRR expression (weak/intense) in renal tumour tissues’ pathological and clinical variables
were tested by Chi-square (χ2) test. Cancer-specific survival (CSS) analysis was performed
by long-rank test with a cut-off point based on the categorical expression of PRR.
3. Results
3.1. Kidney Tumours Express PRR
The uninvolved part of the kidney showed more intense staining in tubules from
the distal nephron than from proximal ones (Figure 1). PRR staining is distributed as
cytoplasmic granular staining of renal cells and concentrates close to the cell membrane.
This distribution corresponds both to the cell-surface and the cytoplasmic organelles.
Same as has been observed in normal renal tubules, the different subtypes of renal
cell carcinomas (CCRCC, PRCC and ChRCC) and RO expressed PRR in the cytoplasm and
plasmatic membrane of tumour cells (Figure 2a). Only one case in all the series was PRR
negative, so data from IHC analysis are represented by two values: weak and intense.
Nearly half of CCRCCs and PRCCs showed weak staining of PRR, whereas in ChRCC
and RO, the staining was mainly intense. Significant differences were found between tumours
from distal and proximal nephron both in the centre and tumour front (Figure 2b,c).
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Figure 1. Immunohistochemical (Pro)renin Receptor (PRR) staining in non-tumour renal tissue.
Hematoxylin–Eosin and PRR immunostaining at the uninvolved part of the kidney. Original magni-
fication, ×250. Red arrows point to proximal tubules with weak PRR expression. Blue arrows point
to distal nephron tubules with intense PRR staining.




Figure 2. Immunohistochemical PRR staining in kidney tumours. (a) PRR immunostaining of dif-
ferent tumor subtypes (clear cell renal cell carcinoma (CCRCC); papillary renal cell carcinoma 
(PRCC); chromophobe renal cell carcinoma (ChRCC); renal oncocytoma (RO)). Original magnifica-
tion, x250. PRR staining intensity both at centre (b) and front (c) of tumours was grouped as weak 
and intense. ChRCCs and RO showed intense PRR staining, whereas CCRCC and PRCC showed 
weak staining. Chi-square test was used for data analysis. H&E: Hematoxilin–Eosin. 
3.2. PRR Expression in CCRCC Changes Depending on Tumour Aggressiveness 
Figure 2. Conts.
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We also compared differences in the expression of PRR between the tumour centre and
front in each kidney tumour subtype. Both tumour locations showed a similar staining pattern
in CCRCC (Chi-square test, p = 0.6), PRCC (p= 0.64), ChRCC (p = 0.3) and RO (p = 0.31).
3.2. PRR Expression in CCRCC Changes Depending on Tumour Aggressiveness
Data from CCRCC tumours were stratified by pathological parameters that were
tightly related to tumour aggressiveness such as WHO/ISUP histological grade, tumour
necrosis, tumour size, local invasion (pT), the presence/absence of affected lymph nodes
(N) and metastases (M), TNM stage and tumour progression (SSIGN scale). The association
between PRR and clinical variables such as patients’ sex, age, mortality risk (UISS scale),
and 5-year cancer-specific survival was also analysed.
The non-parametric Rho Spearman test was performed to assess if PRR protein expres-
sion varies according to the gender or age of the patients. Results showed no statistically
significant correlation between PRR and sex (expression in tumour centre: Spearman Rho,
r = 0.061, p = 0.58; tumour front: r = −0.01, p = 0.99) and age (expression in tumour centre:
r= 0.176, p = 0.11; tumour front: r= 0.183, p = 0.12).
3.2.1. PRR Expression is Higher in High Grade CCRCCs
We stratified cases as low- (G1–G2) and high histological grade (G3–G4). High-grade
CCRCCs expressed significantly stronger PRR staining than low-grade tumours, both at
the centre and at the infiltrating front (Figure 3).
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Figure 3. PRR expression according to tumour grade. Immunostaining at the tumour centre of low-
and high-grade CCRCCs (a). Original magnification, ×250. H&E: Hematoxilin–Eosin. PRR staining
intensity both at centre (b) and front (c) of tumours was grouped as weak and intense. Staining was
more intense in high-grade CCRCCs. Chi-square test was used for data analysis.
3.2.2. PRR Staining is Stronger in Large Tumours
CCRCCs were classified in three groups following previously reported classifica-
tions [27,32]: tumours with 4 cm or smaller, 4 to 7 cm, and larger than 7 cm. PRR staining
was more intense in larger CCRCCs than in small or medium ones. The difference was
statistically significant at the centre of the tumour (Figure 4a,b).
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3.2.3. PRR Expression is Higher in CCRCCs with Higher Local Invasion (pT)
The series had a limited number of pT4 cases and we stratified local invasion in three
groups: pT1 (organ-confined tumours ≤7 cm), pT2 (organ-confined tumours >7 cm) and
pT3-pT4 (non-organ-confined tumours). PRR expression at the centre and at the infiltration
front of pT2 tumours was significantly higher than in pT1 ones. Non-organ-confined
tumours also showed stronger staining of PRR than pT1 ones, with significant results at
the tumour centre (Figure 4c,d).
3.2.4. PRR Expression Does Not Vary Significantly in Metastasized and Not Metastasized
CCRCCs
Tumours that invaded locorregional lymph nodes (N1) showed a similar trend, to-
wards more intense PRR staining than tumours without lymph node invasion (N0), but
data were not statistically significant (at tumour centre, Chi-square p = 0.23; at tumour front,
p = 0.33) (Figure 4e,f). Similarly, PRR expression was higher in CCRCCs with distant metas-
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tasis (M1) than in tumours without, but not significantly (at tumour centre, Chi-square
p = 0.23; at tumour front, p = 0.39) (Figure 4g,h).
3.2.5. PRR Expression is Significantly Higher in High Stage Tumours
CCRCCs were stratified as low-stage (Stage I–II) and advanced- or high-stage (Stages
III–IV). PRR staining at the centre of tumours was stronger in advanced than in low-stage
CCRCCs (Figure 4i,j).
3.2.6. PRR Expression is Higher in CCRCC Patients with Intermediate and High Mortality
Risk (UISS)
We used two validated scales that predict tumour progression and mortality risk
of CCRCC patients: the Mayo Clinic stage, size, grade, necrosis (SSIGN) model [33]
and the UCLA Integrated Staging System (UISS) model [34]. SSIGN scale was strati-
fied in two groups (low vs. high progression), and UISS was classified in three groups
(low vs. intermediate vs. high mortality risk). We also had data of patients’ 5-year cancer-
specific survival (CSS). The association between SSIGN (Log-rank test, p = 0.026) and UISS
scales (Log-rank test, p = 0.013 × 10−5) and 5-year CSS was statistically significant.
PRR at the tumour centre and front showed more intense PRR staining in patients with
intermediate and high mortality risk (UISS) than in those with low risk (Figure 5a,b). However,
this expression was not associated to the SSIGN scale (PRR at tumour centre, Chi-square test
p = 0.23; PRR at tumour front, p = 0.12) (Figure 5c,d), or to the 5-year CSS of these patients
(PRR at tumour centre, Log-rank test p = 0.381; PRR at tumour front, p = 0.857).
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4. Discussion
RCC is a complex and heterogeneous tumour with only two first-line therapeutic
approaches with some efficacy at present: the inhibition of angiogenic pathways by tyrosine-
kinase inhibitors (TKIs) and the improvement in anti-tumour immunity by recently in-
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cluded immune checkpoint inhibitors (ICIs) [35]. Clinical data demonstrated that the
concomitant use of RASis improves the response to TKI treatment in metastasic RCC
patients [16–18]. Preclinical studies supported these data, demonstrating a “hypertro-
phy” of the ACE/AngII/AT1R axis in RCC tissues and proangiogenic and proinvasive
effects of AT1R stimulation by AngII [9,13–15]. Moreover, it has been demonstrated that
AngII/AT1R-signaling contributes to an immunosuppressive microenvironment in differ-
ent ways and that RASis are promising drugs to improve the response to ICIs [36].
The second most-known axis of the RAS, the ACE2/Ang1-7/Mas axis, counterbal-
ances the actions of AngII. Anti-tumour effects of this axis have been demonstrated in
several solid cancers [9,11]; however, its role in RCC development is more controver-
sial [9,11]. On the one hand, it was shown that Ang1-7 induced protumour and proinvasive
phenomena in RCC cell lines through Mas/AKT-signalling pathways [37] and that ACE2
protein expression was higher in high-grade CCRCCs [15]. On the other hand, it has
recently been described that higher ACE2 mRNA levels in CCRCC are associated with
better survival of RCC patients and better response to immunotherapy [38].
The place of PRR in the complex scheme of RAS and renal cancer remains to be deter-
mined. As previously reported [12], we observed that this protein is expressed in proximal
tubules and in the distal nephron of the uninvolved kidney. Both are topographic origins of
the main renal tumours [5] and, as expected, PRR is expressed in three subtypes of RCCs.
Besides this, the staining of this protein was more intense in CCRCCs with high histological
grade, diameter and stage, and was associated with a higher risk of mortality according to the
UISS scale. These results agree with studies carried out in other solid tumours, showing the
potential of PRR as a biomarker of worse prognosis [21]. Furthermore, we reported recently
that PRR staining was not very different in the centre and front of colorectal cancers [27], a
result that was repeated in RCCs. This finding suggests that the intrinsic heterogeneity of
these tumours may not affect their analysis, which is favourable for the potential use of PRR
as an immunohistochemical prognostic biomarker [27].
The mechanism by which PRR upregulation could affect the progression of kidney
could be RAS-dependent or -independent [12,21]. It is known that under pathologic condi-
tions, PRR induces AngII/AT1R-dependent secretion of pro-fibrotic and pro-inflammatory
cytokines in cells from the proximal and distal nephron [12]. Treatment with the renin
inhibitor aliskiren demonstrated antiproliferative effects of RCC [39]; therefore, it could be
hypothesized that the upregulation of PRR could enhance renin activity, contributing to
the stimulation of ACE/AngII/AT1R axis in RCC tissues.
The binding of renin or prorenin to PRR can activate the PI3/AKT/mTOR pathway
independently of the action of angiotensins [12,21]. This is a well-known oncogenic
pathway, which is aberrantly active in CCRCC [40]. Furthermore, PRR is also an important
component of the Wnt receptor complex and acts as an adaptor between LRP6 and the
V-ATPase. This facilitates the binding of Wnt ligands to the Wnt receptor complex and the
activation of the Wnt/β-catenin signalling [12,21] pathway, which is also involved in the
pathogenesis of RCC [41]. Recent findings demonstrate that the increased PRR expression
can lead to an increase in the activity of these signalling routes in other solid tumours [21],
therefore, similar RAS-independent mechanisms should be also taking into account in
renal carcinogenetic processes.
PRR can be found in the cell-surface but also in the cytoplasmic organelles. The protein
is expressed in the membranes of the endoplasmic reticulum and the Golgi apparatus,
from which it can be released as a soluble isoform (sPRR) after cleaving by ADAM19,
furin and Site-1 protease [12,42]. The antibody we used for the IHC analysis detects both
membrane-bound and soluble isoforms [42,43]. The sPRR is released to the extracellular
space and is found in plasma and urine, where it has been described as a potential diagnos-
tic and/or prognostic indicator of cancer presence and progression [21,22]. PRR is also an
essential subunit of vacuolar V-ATPase, a protein complex necessary for the acidification
of intracellular compartments (such us lysosomes) and for the regulation of autophagy.
This is an important homeostatic phenomenon for neoplastic cells to protect them from
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intracellular stress, and PRR is also involved in tumour cell proliferation and progression
by promoting autophagy [12,21,44,45]. Our data show cytoplasmic granular staining of
PRR in RCCs, which could be associated with these intracellular phenomena.
PRR has also been described in benign tumours, such as adrenal [46,47] and colorectal
adenomas [27]. In agreement with this, our results showed that PRR was expressed in RO
and with the same intensity as in ChRCC, tumours that are histogenetically related [6]. These
findings suggest that this protein could induce proliferative but non-invasive signals in some
tumours. It should also be noted that, in a previous analysis, we observed that neither ACE
nor ACE2 were expressed in RO and ChRCC [15], which suggests that the role of PRR in these
tumours could be RAS-independent. The degree to which PRR exerts its RAS-dependent or
-independent actions in each kidney tumour subtype and the way in which this affects the
onset and progression of the tumour is an issue that needs further investigation.
In summary, this study describes PRR protein in a series of kidney tumours with
different topographic origins in the nephron. Furthermore, the results in CCRCCs show
that the protein expression is increased in both the centre and the invasive front of the
most advanced tumours, as has been observed in other solid tumours [21–29]. Taken
together, this evidence indicates that PRR is associated with renal cancer development and
progression. Its potential as a novel biomarker for renal cancer diagnosis and prognosis,
but also as a promising therapeutic target, should be taken into account in the future [21].
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